Out of 336 initial submissions across both Business and NPO Tracks, DiaTheris is the winner of Switzerland's leading early-stage startups...

DiaTheris adjunct treatment to insulin therapy is one of the six startups to win the first stage prize issued in Venture Kick funding...

https://www.unige.ch/medecine/phym/en/home/an-innosuisse-grant-for-a-game-changing-diabetes-treatment/ Type 1 diabetes is a disease in...

Diatheris will be presented at the Swiss Accelerators' Showcase taking place the 28 November 2022. Meet the founders in the virtual 3D...

DIATHERIS has been awarded the Innovation Trophy 2022. The "Diatheris" project, which is developing an approach aimed at overcoming the...

L'università di Ginevra lavora su una terapia alternativa basata sulla proteina S100A9, che può regolare la glicemia, i chetoni e i...

Unrestrained ketogenesis leads to life-threatening ketoacidosis whose incidence is high in patients with diabetes. While insulin therapy...

A UNIGE team reveals how the S100A9 protein improves metabolism of insulin-dependent diabetics by avoiding the deleterious effects of...